// App-Quantinova.ai

353 : Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC

Researchers

Presenter

  • Antonio Jimeno

Principal Investigators

  • Sophie Papa

  • Missak Haigentz

  • Juan Rodrguez-Moreno

  • Julian Schardt

  • Maria Fardis

  • Friedrich Graf Finckenstein

  • Rana Fiaz

  • Guang Chen

  • Alex Cacovean

  • Zelanna Goldberg

  • Ammar Sukari

Medical Centers

  • University of Colorado Cancer Center, Aurora, CO

  • Guys and St Thomas Hospitals NHS Foundation Trust, London, UK

  • Atlantic Health Systems – Morristown, Morristown, NJ, USA

  • Hospital Universitario HM Sanchinarro, Sanchinarro, Spain

  • Universitatsspital Bern, Bern, Switzerland

  • Iovance Biotherapeutics, Inc, San Carlos, CA

  • Iovance Biotherapeutics, Inc, San Carlos, CA

  • Karmanos Cancer Center, Detroit, MI, USA,

Locations

  • United States

  • United Kingdom

  • Spain

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

Biomarkers

  • Glomeruloid microvascular proliferation

  • Interleukin-2

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Pembrolizumab

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved